{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:29:07Z","timestamp":1784842147828,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jbspin.2015.03.013","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T07:40:30Z","timestamp":1444722030000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Allopurinol and kidney function: An update"],"prefix":"10.1016","volume":"83","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2015.03.013_bib0265","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US General Population: NHANES 2007\u20132008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0270","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-198611050-00001","article-title":"Clinical pharmacokinetics of allopurinol","volume":"11","author":"Murrell","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jbspin.2010.02.027","article-title":"The genetic basis of hyperuricaemia and gout","volume":"78","author":"Merriman","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0285","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1124\/dmd.105.006056","article-title":"Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone","volume":"33","author":"Iwanaga","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ng.2500","article-title":"Genome-wide association analyses identify 18 new loci associated with serum urate concentrations","volume":"45","author":"Kottgen","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0295","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.12126","article-title":"Understanding the dose-response relationship of allopurinol: predicting the optimal dosage","volume":"76","author":"Graham","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0300","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0305","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00007611-197911000-00004","article-title":"Severe hypersensitivity reactions to allopurinol","volume":"72","author":"Lang","year":"1979","journal-title":"South Med J"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0310","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0315","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0320","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0325","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","article-title":"Allopurinol hypersensitivity: a systematic review of all published cases, 1950\u20132012","volume":"36","author":"Ramasamy","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0330","first-page":"842","article-title":"Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity","volume":"16","author":"Puig","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0335","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-4684-5673-8_43","article-title":"The allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels","volume":"253A","author":"Casas","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0340","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","article-title":"Plasma oxypurinol concentrations during allopurinol therapy","volume":"26","author":"Emmerson","year":"1987","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0345","first-page":"S561","article-title":"Relationship between serum urate and plasma oxypurinol\u00a0\u2013\u00a0is there a target plasma oxypurinol to achieve serum urate\u00a0<\u00a06mg\/dL?","volume":"60","author":"Stamp","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0350","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily medicated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0355","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01","volume":"192","author":"Yun","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0360","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0365","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0370","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0380","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0385","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"155","author":"Peyriere","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0390","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0395","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0400","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","article-title":"Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005","volume":"67","author":"Annemans","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0405","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.1988.tb03401.x","article-title":"Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion","volume":"26","author":"Day","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0410","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relationship between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0415","first-page":"S414","article-title":"Allopurinol hypersensitivity reactions: a case-control study of the role of renal dosing","volume":"60","author":"Silverberg","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0420","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0425","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0430","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/M14-0227","article-title":"Cost-effectiveness of allopurinol and febuxostat for the management of gout","volume":"161","author":"Jutkowitz","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0435","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/ard.25.Suppl_6.694","article-title":"Allopurinol in gouty nephropathy and renal dialysis","volume":"25","author":"Rundles","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0440","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00002480-196504000-00047","article-title":"The use of allopurinol to control hyperuricaemia in patients on chronic intermittent hemodialysis","volume":"XI","author":"Hayes","year":"1965","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0445","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.02.2012.5814","article-title":"Successful use of allopurinol in a patient on dialysis","author":"Day","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0450","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3346\/jkms.2014.29.8.1077","article-title":"Four week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men","volume":"29","author":"Kim","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0455","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","article-title":"Improvement of renal function in patients with chronic gout after proper control of hyperuricaemia and gouty bouts","volume":"86","author":"Perez-Ruiz","year":"2000","journal-title":"Nephron"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0460","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"56","author":"Bellomo","year":"2010","journal-title":"Am J Kid Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0465","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000045939","article-title":"Serum uric acid and renal prognosis in patients with IgA nephropathy","volume":"87","author":"Ohno","year":"2001","journal-title":"Nephron"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0470","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-0227","article-title":"High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes","volume":"33","author":"Ficociello","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0475","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significant hyperuricaemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kid Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0480","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kid Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0485","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","article-title":"A randomized study of allopruinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricaemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0490","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1681\/ASN.2010111185","article-title":"Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease","volume":"22","author":"Kao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0495","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000331453","article-title":"Clinical outcome of hyperuricaemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial","volume":"35","author":"Shi","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0500","article-title":"Allopurinol treatment improves renal fucntion in patients with type 2 diabetes and asymptomatic hyperuricaemia: a three year randomized parallel-controlled trial","author":"Liu","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0505","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0510","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long term followup of a rondomised controlled trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0515","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ndt\/gft378","article-title":"Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis","volume":"29","author":"Bose","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2015.03.013_bib0520","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/jamainternmed.2014.1427","article-title":"Allopurinol overuse in asymptomatic hyperuricemia: a teachable moment","volume":"174","author":"Carnovale","year":"2014","journal-title":"JAMA Int Med"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X15001645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X15001645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:36:15Z","timestamp":1748651775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X15001645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1297319X15001645"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2015.03.013","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allopurinol and kidney function: An update","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2015.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}